Scarica l'app Stockscreener
9.375
3.05%
-0.295
Precedente Chiudi:
$9.67
Aprire:
$9.69
Volume 24 ore:
79,338
Relative Volume:
0.75
Capitalizzazione di mercato:
$149.46M
Reddito:
-
Utile/perdita netta:
$-14.72M
Rapporto P/E:
-3.3127
EPS:
-2.83
Flusso di cassa netto:
$-7.41M
1 W Prestazione:
+0.48%
1M Prestazione:
+34.70%
6M Prestazione:
+65.64%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$9.05
$10.10
Intervallo di 1 settimana:
$8.845
$10.35
Portata 52W:
$3.75
$11.40
Alpha Cognition Inc Stock (ACOG) Company Profile
Nome
Alpha Cognition Inc
Settore
Industria
Telefono
(858) 344-4375
Indirizzo
1200-750 W PENDER ST, VANCOUVER
Confronta ACOG con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ACOG
Alpha Cognition Inc
|
9.375 | 149.46M | 0 | -14.72M | -7.41M | -2.83 |
|
VRTX
Vertex Pharmaceuticals Inc
|
450.50 | 113.52B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
493.22 | 52.93B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
300.83 | 39.71B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
585.93 | 35.00B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
255.86 | 26.57B | 3.81B | -644.79M | -669.77M | -6.24 |
Alpha Cognition Inc Stock (ACOG) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-18 | Iniziato | H.C. Wainwright | Buy |
Alpha Cognition Inc Borsa (ACOG) Ultime notizie
Alpha Cognition Inc. Common Stock (ACOG): A Bull Case Theory - Insider Monkey
Alpha Cognition Inc. Common Stock (NASDAQ:ACOG) Q1 2025 Earnings Call Transcript - MSN
Alpha Cognition: Launching A Differentiated Drug Into A Large Alzheimer's Market Opportunity - Seeking Alpha
Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) Q1 2025 - TradingView
Alpha Cognition (NASDAQ:ACOG) Earns “Buy” Rating from HC Wainwright - Defense World
We Think Alpha Cognition (NASDAQ:ACOG) Can Easily Afford To Drive Business Growth - Yahoo Finance
Alpha Cognition Inc. Reports Strong Q1 2025 Performance - TipRanks
Alpha Cognition’s Earnings Call Highlights Success and Growth - TipRanks
Alpha Cognition’s Strong Financial Performance and Promising Alzheimer’s Treatment Drive Buy Rating - TipRanks
Alpha Cognition Inc. (ACOG) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
Alpha Cognition Q1 2025 Earnings Call Transcript - MarketBeat
ALPHA COGNITION Earnings Results: $ACOG Reports Quarterly Earnings - Nasdaq
Alpha Cognition Inc. SEC 10-Q Report - TradingView
Alpha Cognition Inc. Reports First Quarter 2025 Financial Results and Operating Overview - BioSpace
Alpha Cognition (ACOG) Expected to Announce Earnings on Tuesday - Defense World
Alpha Cognition, Inc.’s (NASDAQ:ACOG) Lock-Up Period To Expire on May 12th - Defense World
Will Alpha Cognition's Recently Launched Alzheimer's Drug Be A Commercial Success? - RTTNews
Alpha Cognition to Report First Quarter 2025 Financial Results and Operating Overview - BioSpace
Alpha Cognition, Inc. Announces Participation in the D. Boral Capital Inaugural Global Conference - The Kingston Whig Standard
Alpha Cognition to Present ZUNVEYL® (Benzgalantamine) Clinical Data at 2025 Alzheimer’s Association International Conference - Yahoo Finance
(Benzgalantamine) Clinical Data at 2025 Alzheimer’s Association International Conference - Business Wire
Alpha Cognition Inc. Reports Strong 2024 Financials - TipRanks
Alpha Cognition Strengthens Its Leadership Team with Appointment of Robert Wills to Board of Directors and Announces Departure of Existing Director John Havens - BioSpace
Alpha Cognition announces board changes - Investing.com
Alpha Cognition announces board changes By Investing.com - Investing.com Canada
Alpha Cognition Appoints Robert Wills To Board - citybiz
Alpha Cognition Earnings Call: Positive Outlook Amid Growth - TipRanks
Alpha Cognition Announces a $44 Million Exclusive Licensing Agreement for the Development and Commercialization of ZUNVEYL (benzgalantamine), an FDA-Approved Treatment for Mild-to-Moderate Alzheimer’s Disease, in China - The Globe and Mail
Alpha Cognition stock hits 52-week low at $4.65 amid downturn - Investing.com Canada
HC Wainwright Expects Stronger Earnings for Alpha Cognition - Defense World
Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) Q4 2024 - TradingView
Alpha Cognition (NASDAQ:ACOG) Given Buy Rating at HC Wainwright - Defense World
Alpha Cognition Inc. (ACOG) reports earnings - Quartz
Alpha Cognition Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Operating Overview - Business Wire
Earnings Scheduled For March 31, 2025 - Benzinga
Comparing Alpha Cognition (ACOG) and The Competition - Defense World
Alpha Cognition (NASDAQ:ACOG) Upgraded at Raymond James - Defense World
Contrasting Alpha Cognition (NASDAQ:ACOG) & Cognition Therapeutics (NASDAQ:CGTX) - Defense World
Alpha Cognition (ACOG) Projected to Release Quarterly Earnings on Wednesday - Defense World
Alpha Cognition Inc Azioni (ACOG) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.21%
1.51%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):